{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:40:43Z","timestamp":1775792443519,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["320030_169876"],"award-info":[{"award-number":["320030_169876"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["115952"],"award-info":[{"award-number":["115952"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To review how outcomes of clinical utility are operationalized in current amyloid-PET validation studies, to prepare for formal assessment of clinical utility of amyloid-PET-based diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Systematic review of amyloid-PET research studies published up to April 2020 that included outcomes of clinical utility. We extracted and analyzed (a) outcome categories, (b) their definition, and (c) their methods of assessment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-two studies were eligible. (a) Outcome categories were <jats:bold>clinician-centered<\/jats:bold> (found in 25\/32 studies, 78%), <jats:bold>patient-\/caregiver-centered<\/jats:bold> (in 9\/32 studies, 28%), and <jats:bold>health economics-centered<\/jats:bold> (5\/32, 16%). (b) Definition: Outcomes were mainly defined by clinical researchers; only the ABIDE study expressly included stakeholders in group discussions. Clinician-centered outcomes mainly consisted of incremental diagnostic value (25\/32, 78%) and change in patient management (17\/32, 53%); patient-\/caregiver-centered outcomes considered distress after amyloid-pet-based diagnosis disclosure (8\/32, 25%), including quantified burden of procedure for patients\u2019 outcomes (<jats:italic>n<\/jats:italic> = 8) (1\/8, 12.5%), impact of disclosure of results (6\/8, 75%), and psychological implications of biomarker-based diagnosis (75%); and health economics outcomes focused on costs to achieve a high-confidence etiological diagnosis (5\/32, 16%) and impact on quality of life (1\/32, 3%). (c) Assessment: all outcome categories were operationalized inconsistently across studies, employing 26 different tools without formal rationale for selection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Current studies validating amyloid-PET already assessed outcomes for clinical utility, although non-clinician-based outcomes were inconsistent. A wider participation of stakeholders may help produce a more thorough and systematic definition and assessment of outcomes of clinical utility and help collect evidence informing decisions on reimbursement of amyloid-PET.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-020-05187-x","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T02:34:53Z","timestamp":1613702093000},"page":"2157-2168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-9648","authenticated-orcid":false,"given":"Matteo","family":"Cotta Ramusino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Perini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Altomare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Barbarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Weidner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Salvini Porro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil D.","family":"Rabinovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni B.","family":"Frisoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Boccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"issue":"3","key":"5187_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292\u2013323.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"5187_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"C Jack Jr","year":"2018","unstructured":"Jack C Jr, Bennet DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"5187_CR3","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/ene.12043","volume":"20","author":"MA Leone","year":"2013","unstructured":"Leone MA, Brainin M, Boon P, Pugliatti M, Keindl M, Bassetti CL. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2012. Eur J Neurol. 2013;20(3):410\u20139.","journal-title":"Eur J Neurol"},{"key":"5187_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.neurobiolaging.2017.01.021","volume":"52","author":"M Boccardi","year":"2017","unstructured":"Boccardi M, Gallo V, Yasui Y, Vineis P, Padovani A, Mosimann U, et al. The biomarker-based diagnosis of Alzheimer\u2019s disease. 2-lessons from oncology. Neurobiol Aging. 2017;52:141\u201352.","journal-title":"Neurobiol Aging"},{"issue":"8","key":"5187_CR5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16(8):661\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(17)30159-X.","journal-title":"Lancet Neurol"},{"key":"5187_CR6","doi-asserted-by":"publisher","unstructured":"Boccardi M, Dodich A, Albanese E, Gayet-Ageron A, Festari C, Ashton NJ, et al. The strategic biomarker roadmap for the validation of Alzheimer\u2019s diagnostic biomarkers: methodological update. EJNMMI. 2020. https:\/\/doi.org\/10.1007\/s00259-020-05120-2.","DOI":"10.1007\/s00259-020-05120-2"},{"key":"5187_CR7","unstructured":"FDA. Early Alzheimer\u2019s disease: developing drugs for treatment, guidance for industry. Food and Drug Administration; 2018."},{"key":"5187_CR8","unstructured":"EMA. Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. European Medicine Agency; 2018."},{"issue":"3","key":"5187_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jalz.2018.09.003","volume":"15","author":"GB Frisoni","year":"2019","unstructured":"Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, et al. AMYPAD Diagnostic and patient management study: rationale and design. Alzheimers Dement. 2019;15(3):388\u201399. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.003.","journal-title":"Alzheimers Dement"},{"key":"5187_CR10","unstructured":"Imaging Dementia-Evidence for Amyloid Scanning (IDEAS). Website: https:\/\/www.ideas-study.org\/."},{"key":"5187_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.dadm.2017.01.003","volume":"6","author":"A de Wilde","year":"2017","unstructured":"de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, et al. Alzheimer\u2019s biomarkers in daily practice (ABIDE) project: rationale and design. Alzheimers Dement (Amst). 2017;6:143\u201351. https:\/\/doi.org\/10.1016\/j.dadm.2017.01.003.","journal-title":"Alzheimers Dement (Amst)"},{"key":"5187_CR12","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preffered reporting Items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"5187_CR13","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1159\/000345783","volume":"2","author":"KS Frederiksen","year":"2012","unstructured":"Frederiksen KS, Hasselbalch SG, Hejl AM, Law I, H\u00f8jgaard L, Waldemar G. Added diagnostic value of (11)C-PiB-PET in memory clinic patients with uncertain diagnosis. Dement Geriatr Cogn Dis Extra. 2012;2(1):610\u201321. https:\/\/doi.org\/10.1159\/000345783.","journal-title":"Dement Geriatr Cogn Dis Extra."},{"issue":"6","key":"5187_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1159\/000339367","volume":"33","author":"CG Schipke","year":"2012","unstructured":"Schipke CG, Peters O, Heuser I, Grimmer T, Sabbagh MN, Sabri O, et al. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2012;33(6):416\u201322.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"5187_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1159\/000356273","volume":"3","author":"M Degerman Gunnarsson","year":"2013","unstructured":"Degerman Gunnarsson M, Lindau M, Santillo AF, Wall A, Engler H, Lannfelt L, et al. Re-evaluation of clinical dementia diagnoses with pittsburgh compound B positron emission tomography. Dement Geriatr Cogn Dis Extra. 2013;3(1):472\u201381. https:\/\/doi.org\/10.1159\/000356273.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"1","key":"5187_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/WAD.0b013e318279d02a","volume":"27","author":"M Grundman","year":"2013","unstructured":"Grundman M, Pontecorvo MJ, Salloway SP, Murali Doraiswamy P, Fleisher AS, Sadowsky CA, et al. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013;27(1):4\u201315. https:\/\/doi.org\/10.1097\/WAD.0b013e318279d02a.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"4","key":"5187_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jalz.2012.07.003","volume":"9","author":"R Ossenkoppele","year":"2013","unstructured":"Ossenkoppele R, Prins ND, Pijnenburg YA, Lemstra AW, van der Flier WM, Adriaanse SF, et al. Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement. 2013;9(4):414\u201321. https:\/\/doi.org\/10.1016\/j.jalz.2012.07.003.","journal-title":"Alzheimers Dement"},{"key":"5187_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1750-1326-9-10","volume":"9","author":"EM Mitsis","year":"2014","unstructured":"Mitsis EM, Bender HA, Kostakoglu L, Machac J, Martin J, Woehr JL, et al. A consecutive case series experience with [18\u2009F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener. 2014;9:10. https:\/\/doi.org\/10.1186\/1750-1326-9-10.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"5187_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1212\/WNL.0000000000000032","volume":"82","author":"P S\u00e1nchez-Juan","year":"2014","unstructured":"S\u00e1nchez-Juan P, Ghosh PM, Hagen J, Gesierich B, Henry M, Grinberg LT, et al. Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology. 2014;82(3):230\u20138. https:\/\/doi.org\/10.1212\/WNL.0000000000000032.","journal-title":"Neurology."},{"issue":"4","key":"5187_CR20","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/13554794.2013.791867","volume":"20","author":"AS Zannas","year":"2014","unstructured":"Zannas AS, Doraiswamy PM, Shpanskaya KS, Murphy KR, Petrella JR, Burke JR, et al. Impact of 18F-florbetapir PET imaging of \u03b2-amyloid neuritic plaque density on clinical decision-making. Neurocase. 2014;20(4):466\u201373. https:\/\/doi.org\/10.1080\/13554794.2013.791867.","journal-title":"Neurocase."},{"issue":"7","key":"5187_CR21","doi-asserted-by":"publisher","first-page":"P1161","DOI":"10.1016\/j.jalz.2016.07.076","volume":"12","author":"K Ishii","year":"2016","unstructured":"Ishii K, Ishibashi K, Sakata M, Wagatsuma K, Toyohara J, Murayama S. Clinical impact of amyloid PET with [C-11] Pittsburgh compound b on the diagnosis of early onset dementias. Alzheimers Dement. 2016;12(7):P1161\u20132.","journal-title":"Alzheimers Dement"},{"issue":"1-2","key":"5187_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000441139","volume":"41","author":"M Grundman","year":"2016","unstructured":"Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, et al. Effect of amyloid imaging on the diagnosis and management of patients with cognitive decline: impact of appropriate use criteria. Dement Geriatr Cogn Disord. 2016;41(1-2):80\u201392. https:\/\/doi.org\/10.1159\/000441139.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12","key":"5187_CR23","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaneurol.2016.3751","volume":"73","author":"M Boccardi","year":"2016","unstructured":"Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, et al. Assessment of the incremental diagnostic value of Florbetapir F 18 imaging in patients with cognitive impairment: the incremental diagnostic value of amyloid PET with [18F]-Florbetapir (INDIA-FBP) study. JAMA Neurol. 2016;73(12):1417\u201324.","journal-title":"JAMA Neurol."},{"issue":"4","key":"5187_CR24","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3233\/JAD-151180","volume":"52","author":"MR Bensa\u00efdane","year":"2016","unstructured":"Bensa\u00efdane MR, Beauregard JM, Poulin S, Buteau F, Guimond J, Bergeron D, et al. Clinical utility of amyloid PET imaging in the differential diagnosis of atypical dementias and its impact on caregivers. J Alzheimers Dis. 2016;52(4):1251\u201362. https:\/\/doi.org\/10.3233\/JAD-151180.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"5187_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3233\/JAD-160302","volume":"54","author":"PS Weston","year":"2016","unstructured":"Weston PS, Paterson RW, Dickson J, Barnes A, Bomanji JB, Kayani I, et al. Diagnosing dementia in the clinical setting: can amyloid PET provide additional value over cerebrospinal fluid? J Alzheimers Dis. 2016;54(4):1297\u2013302. https:\/\/doi.org\/10.3233\/JAD-160302.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"5187_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jalz.2017.09.009","volume":"14","author":"M Ceccaldi","year":"2018","unstructured":"Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, et al. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: a naturalistic study. Alzheimers Dement. 2018;14(3):293\u2013305. https:\/\/doi.org\/10.1016\/j.jalz.2017.09.009.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"5187_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/jnnp-2017-316194","volume":"89","author":"CJ Carswell","year":"2018","unstructured":"Carswell CJ, Win Z, Muckle K, Kennedy A, Waldman A, Dawe G, et al. Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients. J Neurol Neurosurg Psychiatry. 2018;89(3):294\u20139. https:\/\/doi.org\/10.1136\/jnnp-2017-316194.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"5187_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-016-0228-4","volume":"9","author":"MD Zwan","year":"2017","unstructured":"Zwan MD, Bouwman FH, Konijnenberg E, van der Flier WM, Lammertsma AA, Verhey FRJ, et al. Diagnostic impact of [18F] flutemetamol PET in early-onset dementia. Alzheimers Res Ther. 2017;9(1):2. https:\/\/doi.org\/10.1186\/s13195-016-0228-4.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"5187_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/WAD.0000000000000168","volume":"31","author":"Y Zhong","year":"2017","unstructured":"Zhong Y, Karlawish J, Johnson MK, Neumann PJ, Cohen JT. The potential value of \u03b2-amyloid imaging for the diagnosis and management of dementia: a survey of clinicians. Alzheimer Dis Assoc Disord. 2017;31(1):27\u201333. https:\/\/doi.org\/10.1097\/WAD.0000000000000168.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3-4","key":"5187_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000478007","volume":"44","author":"MJ Pontecorvo","year":"2017","unstructured":"Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, et al. Effectiveness of Florbetapir PET imaging in changing patient management. Dement Geriatr Cogn Disord. 2017;44(3-4):129\u201343. https:\/\/doi.org\/10.1159\/000478007.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"5187_CR31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1001\/jamaneurol.2018.1346","volume":"75","author":"A de Wilde","year":"2018","unstructured":"de Wilde A, van der Flier WM, Pelkmans W, Bouwman F, Verwer J, Groot C, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75(9):1062\u201370. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1346.","journal-title":"JAMA Neurol"},{"issue":"6","key":"5187_CR32","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s00259-019-04297-5","volume":"46","author":"A Leuzy","year":"2019","unstructured":"Leuzy A, Savitcheva I, Chiotis K, Lilja J, Andersen P, Bogdanovic N, et al. Clinical impact of [18F] flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J Nucl Med Mol Imaging. 2019;46(6):1276\u201386. https:\/\/doi.org\/10.1007\/s00259-019-04297-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"5187_CR33","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286\u201394. https:\/\/doi.org\/10.1001\/jama.2019.2000.","journal-title":"JAMA."},{"issue":"2","key":"5187_CR34","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00259-019-04466-6","volume":"47","author":"M Cotta Ramusino","year":"2020","unstructured":"Cotta Ramusino M, Garibotto V, Bacchin R, Altomare D, Dodich A, Assal F, et al. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging. 2020;47(2):270\u201380. https:\/\/doi.org\/10.1007\/s00259-019-04466-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"29","key":"5187_CR35","doi-asserted-by":"publisher","first-page":"e16509","DOI":"10.1097\/MD.0000000000016509","volume":"98","author":"EM Trivi\u00f1o-Ib\u00e1\u00f1ez","year":"2019","unstructured":"Trivi\u00f1o-Ib\u00e1\u00f1ez EM, S\u00e1nchez-Va\u00f1\u00f3 R, Sopena-Novales P, Romero-F\u00e1brega JC, Rodr\u00edguez-Fern\u00e1ndez A, Pardo CC, et al. Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria. Medicine (Baltimore). 2019;98(29):e16509. https:\/\/doi.org\/10.1097\/MD.0000000000016509.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"5187_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jalz.2015.09.005","volume":"12","author":"YY Lim","year":"2016","unstructured":"Lim YY, Maruff P, Getter C, Snyder PJ. Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12(4):454\u20138. https:\/\/doi.org\/10.1016\/j.jalz.2015.09.005.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"5187_CR37","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jalz.2017.01.001","volume":"13","author":"JD Grill","year":"2017","unstructured":"Grill JD, Cox CG, Kremen S, Mendez MF, Teng E, Shapira J, et al. Patient and caregiver reactions to clinical amyloid imaging. Alzheimers Dement. 2017;13(8):924\u201332. https:\/\/doi.org\/10.1016\/j.jalz.2017.01.001.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5187_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13195-017-0321-3","volume":"9","author":"G Vanderschaeghe","year":"2017","unstructured":"Vanderschaeghe G, Schaeverbeke J, Bruffaerts R, Vandenberghe R, Dierickx K. Amnestic MCI patients\u2019 experiences after disclosure of their amyloid PET result in a research context. Alzheimers Res Ther. 2017;9(1):92. https:\/\/doi.org\/10.1186\/s13195-017-0321-3.","journal-title":"Alzheimers Res Ther"},{"key":"5187_CR39","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.dadm.2019.06.001","volume":"11","author":"LNC Visser","year":"2019","unstructured":"Visser LNC, Kunneman M, Murugesu L, van Maurik I, Zwan M, Bouwman FH, et al. Clinician-patient communication during the diagnostic workup: the ABIDE project. Alzheimers Dement (Amst). 2019;11:520\u20138. https:\/\/doi.org\/10.1016\/j.dadm.2019.06.001.","journal-title":"Alzheimers Dement (Amst)."},{"key":"5187_CR40","doi-asserted-by":"publisher","first-page":"548157","DOI":"10.1155\/2012\/548157","volume":"2012","author":"S Guo","year":"2012","unstructured":"Guo S, Getsios D, Hernandez L, Cho K, Lawler E, Altincatal A, et al. Florbetaben PET in the early diagnosis of Alzheimer\u2019s disease: a discrete event simulation to explore its potential value and key data gaps. Int J Alzheimers Dis. 2012;2012:548157. https:\/\/doi.org\/10.1155\/2012\/548157.","journal-title":"Int J Alzheimers Dis"},{"issue":"2","key":"5187_CR41","first-page":"63","volume":"18","author":"J Hornberger","year":"2015","unstructured":"Hornberger J, Michalopoulos S, Dai M, Andrade P, Dilla T, Happich M. Cost-effectiveness of florbetapir-pet in Alzheimer\u2019s disease: a Spanish societal perspective. J Ment Health Policy Econ. 2015;18(2):63\u201373.","journal-title":"J Ment Health Policy Econ"},{"key":"5187_CR42","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1080\/03007995.2016.1277197","volume":"33","author":"J Hornberger","year":"2017","unstructured":"Hornberger J, Bae J, Watson I, Johnston J, Happich M. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer\u2019s disease: the case of florbetapir. Curr Med Res Opin. 2017;33:675\u201385.","journal-title":"Curr Med Res Opin"},{"key":"5187_CR43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neurobiolaging.2016.07.012","volume":"52","author":"K Chiotis","year":"2017","unstructured":"Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, et al. Geneva task force for the roadmap of Alzheimer\u2019s biomarkers. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214\u201327. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.07.012.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"5187_CR44","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3233\/JAD-171093","volume":"63","author":"ER Fantoni","year":"2018","unstructured":"Fantoni ER, Chalkidou A. O' Brien JT, Farrar G, Hammers A. A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer\u2019s disease. J Alzheimers Dis. 2018;63(2):783\u201396. https:\/\/doi.org\/10.3233\/JAD-171093.","journal-title":"J Alzheimers Dis"},{"issue":"3-4","key":"5187_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000492151","volume":"46","author":"Y Kim","year":"2018","unstructured":"Kim Y, Rosenberg P, Oh E. A review of diagnostic impact of amyloid positron emission tomography imaging in clinical practice. Dement Geriatr Cogn Disord. 2018;46(3-4):154\u201367. https:\/\/doi.org\/10.1159\/000492151.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"11","key":"5187_CR46","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2967\/jnumed.116.185017","volume":"58","author":"H Barthel","year":"2017","unstructured":"Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58(11):1711\u20137. https:\/\/doi.org\/10.2967\/jnumed.116.185017.","journal-title":"J Nucl Med"},{"key":"5187_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neurobiolaging.2016.03.033","volume":"52","author":"V Garibotto","year":"2017","unstructured":"Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, et al. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:183\u201395. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.03.033.","journal-title":"Neurobiol Aging"},{"issue":"9","key":"5187_CR48","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00259-018-4035-y","volume":"45","author":"PJ Nestor","year":"2018","unstructured":"Nestor PJ, Altomare D, Festari C, Drzezga A, Rivolta J, Walker Z, et al. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1509\u201325. https:\/\/doi.org\/10.1007\/s00259-018-4035-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"5187_CR49","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s00259-018-4024-1","volume":"45","author":"M Boccardi","year":"2018","unstructured":"Boccardi M, Festari C, Altomare D, Gandolfo F, Orini S, Nobili F, et al. Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. Eur J Nucl Med Mol Imaging. 2018;45(9):1470\u201386. https:\/\/doi.org\/10.1007\/s00259-018-4024-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"5187_CR50","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jalz.2014.04.517","volume":"11","author":"J Gooblar","year":"2015","unstructured":"Gooblar J, Carpenter BD, Coats MA, Morris JC, Snider BJ. The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations. Alzheimers Dement. 2015;11(5):533\u2013540.e2. https:\/\/doi.org\/10.1016\/j.jalz.2014.04.517.","journal-title":"Alzheimers Dement"},{"key":"5187_CR51","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neurobiolaging.2016.02.034","volume":"52","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, L\u00f6nneborg A, Boccardi M, Blennow K, Hansson O, Geneva task force for the roadmap of Alzheimer\u2019s biomarkers. Clinical Validity of Cerebrospinal Fluid A\u03b242, Tau, and Phospho-Tau as Biomarkers for Alzheimer's Disease in the Context of a Structured 5-phase Development Framework. Neurobiol Aging. 2017;52:196\u2013213. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2016.02.034.","journal-title":"Neurobiol Aging"},{"issue":"10","key":"5187_CR52","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jamda.2017.01.006","volume":"18","author":"A Bentvelzen","year":"2017","unstructured":"Bentvelzen A, Aerts L, Seeher K, Wesson J, Brodaty H. A comprehensive review of the quality and feasibility of dementia assessment measures: the dementia outcomes measurement suite. J Am Med Dir Assoc. 2017;18(10):826\u201337. https:\/\/doi.org\/10.1016\/j.jamda.2017.01.006.","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"5187_CR53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jalz.2019.09.087","volume":"16","author":"O Janssen","year":"2020","unstructured":"Janssen O, Vos SJB, Garc\u00eda-Negredo G, Tochel C, Gustavsson A, Smith M, et al. Real-world evidence in Alzheimer\u2019s disease: the ROADMAP data cube. Alzheimers Dement. 2020;16(3):461\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2019.09.087.","journal-title":"Alzheimers Dement"},{"key":"5187_CR54","unstructured":"Dementia outcomes measurement suite (DOMS). Website: www.dementia-assessment.com.au [Tool \/ Guide \/ Education, 01-06-2010]."},{"key":"5187_CR55","unstructured":"Real world outcomes across the Alzheimer\u2019s disease spectrum for better care: multi-modal data access platform (ROADMAP) \u2013 interactive data cube. Website: https:\/\/datacube.roadmap-alzheimer.org."},{"issue":"1","key":"5187_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1590\/s0036-36342013000100009","volume":"55","author":"JM Ramada-Rodilla","year":"2013","unstructured":"Ramada-Rodilla JM, Serra-Pujiadas C, Delclos-Clanchet GL. Cross-cultural adaptation and health questionnaires validation: revision and methodological recommendations. Salud Publica Mex. 2013;55(1):57\u201366. https:\/\/doi.org\/10.1590\/s0036-36342013000100009.","journal-title":"Salud Publica Mex"},{"key":"5187_CR57","first-page":"26","volume":"8","author":"RJ Jutten","year":"2017","unstructured":"Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, et al. Detecting functional decline from normal aging to dementia: development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement. 2017;8:26\u201335.","journal-title":"Alzheimers Dement"},{"key":"5187_CR58","unstructured":"WHO. Global action plan on the public health response to dementia 2017-2025. Website: https:\/\/www.who.int\/mental_health\/neurology\/dementia\/action_plan_2017_2025\/en\/."},{"key":"5187_CR59","unstructured":"Prince M, Bryce R, Ferri C. Alzheimer\u2019s Disease International. World Alzheimer Report 2011: the benefits of early diagnosis and intervention. http:\/\/www.alz.co.uk\/research\/WorldAlzheimerReport2011.pdf. Published 2011. Accessed December 5, 2018."},{"key":"5187_CR60","first-page":"CD005562","volume":"2","author":"B Woods","year":"2012","unstructured":"Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012;2:CD005562.","journal-title":"Cochrane Database Syst Rev"},{"key":"5187_CR61","first-page":"CD013069","volume":"3","author":"A Bahar-Fuchs","year":"2019","unstructured":"Bahar-Fuchs A, Martyr A, Goh AM, Sabates J, Clare L. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019;3:CD013069.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"5187_CR62","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jamda.2013.01.006","volume":"14","author":"R Liperoti","year":"2013","unstructured":"Liperoti R, Landi F. The management of behavioral and psychological symptoms of dementia: the need for tailored interventions. J Am Med Dir Assoc. 2013;14(4):306\u20137.","journal-title":"J Am Med Dir Assoc"},{"issue":"5","key":"5187_CR63","doi-asserted-by":"publisher","first-page":"325","DOI":"10.30773\/pi.2019.02.11.2","volume":"16","author":"R Na","year":"2019","unstructured":"Na R, Yang J-H, Yeom Y, Kim YJ, Byun S, Kim K, et al. A systematic review and meta-analysis of nonpharmacological interventions for moderate to severe dementia. Psychiatry Investig. 2019;16(5):325\u201335.","journal-title":"Psychiatry Investig"},{"key":"5187_CR64","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jalz.2009.01.028","volume":"5","author":"DL Weimer","year":"2009","unstructured":"Weimer DL, Sager MA. Early identification and treatment of Alzheimer\u2019s disease: social and fiscal outcomes. Alzheimers Dement. 2009;5:212\u201326.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"5187_CR65","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.22258","volume":"323","author":"CD Patnode","year":"2020","unstructured":"Patnode CD, Perdue LA, Rossom RC, Rushkin MC, Redmond N, Thomas RG, et al. Screening for cognitive impairment in older adults updated evidence report and systematic review for the US Preventive services task force. JAMA. 2020;323(8):764\u201385.","journal-title":"JAMA."},{"issue":"11","key":"5187_CR66","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S1474-4422(20)30365-3","volume":"19","author":"JD Isaacs","year":"2020","unstructured":"Isaacs JD, Boenink M. Biomarkers for dementia: too soon for routine clinical use. Lancet Neurol. 2020;19(11):884\u20135.","journal-title":"Lancet Neurol"},{"issue":"7","key":"5187_CR67","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1164\/rccm.201708-1678ST","volume":"196","author":"PJ Mazzone","year":"2017","unstructured":"Mazzone PJ, Rufatto Sears C, Arenberg DA, Gaga M, Gould MK, Massion PP, et al. ATS assembly on thoracic oncology. evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An Official American Thoracic Society Policy Statement. Am J Respir Crit Care Med. 2017;196(7):e15\u201329. https:\/\/doi.org\/10.1164\/rccm.201708-1678ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"5187_CR68","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1176\/appi.ajp.161.6.946","volume":"161","author":"MB First","year":"2004","unstructured":"First MB, Pincus HA, Levine JB, Williams JB, Ustun B, Peele R. Clinical utility as a criterion for revising psychiatric diagnoses. Am J Psychiatry. 2004;161(6):946\u201354. https:\/\/doi.org\/10.1176\/appi.ajp.161.6.946.","journal-title":"Am J Psychiatry"},{"key":"5187_CR69","doi-asserted-by":"publisher","first-page":"E30","DOI":"10.1177\/0272989X09347013","volume":"29","author":"PM Bossuyt","year":"2009","unstructured":"Bossuyt PM, McCaffery K. Additional patient outcomes and pathways in evaluations of testing. Med Decis Mak. 2009;29:E30\u20138.","journal-title":"Med Decis Mak"},{"key":"5187_CR70","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1056\/NEJMp0912062","volume":"362","author":"PJ Neumann","year":"2010","unstructured":"Neumann PJ, Tunis SR. Medicare and medical technology \u2013 the growing demand for relevant outcomes. N Engl J Med. 2010;362:377\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"5187_CR71","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1373\/clinchem.2012.182576","volume":"58","author":"PMM Bossuyt","year":"2012","unstructured":"Bossuyt PMM, Reitsma JB, Linnet K, Moons KGM. Beyond diagnostic accuracy: the clinical utility of diagnostic tests. Clin Chem. 2012;58(12):1636\u201343.","journal-title":"Clin Chem"},{"key":"5187_CR72","unstructured":"Alzheimer\u2019s Disease International. World Alzheimer Report 2019: Attitudes to dementia. 2019. Website: https:\/\/www.alz.co.uk\/research\/world-report-2019."},{"key":"5187_CR73","unstructured":"Alzheimer\u2019s Disease International. From Plan to Impact III: maintaining dementia as a priority in unprecedented times. 2020. Website: https:\/\/www.alz.co.uk\/adi\/pdf\/from-plan-to-impact-2020.pdf."},{"key":"5187_CR74","unstructured":"CO-desiGning DemeNtia dIagnoSis ANd post-diagnostic CarE (COGNISANCE) project. Website: http:\/\/cheba.unsw.edu.au\/consortia\/cognisance."},{"key":"5187_CR75","unstructured":"Strengthening responses to dementia in developing countries (STRiDE). Website: https:\/\/stride-dementia.org\/."},{"key":"5187_CR76","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","volume":"336","author":"HJ Sch\u00fcnemann","year":"2008","unstructured":"Sch\u00fcnemann HJ, Sch\u00fcnemann AHJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106\u201310.","journal-title":"BMJ."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05187-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05187-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05187-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T08:06:16Z","timestamp":1622707576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05187-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5187"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05187-x","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"13 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"V. Garibotto received financial support for research through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cerveau Technologies, Roche, Merck. G.D. Rabinovici receives research support from the National Institutes of Health, Alzheimer\u2019s Association, American College of Radiology, Rainwater Charitable Foundation, Gift from Edward and Pearl Fein, Avid Radiopharamaceuticals, Eli Lilly, Life Molecular Imaging, GE Healthcare. He has served as a consultant for Axon Neurosciences, Eisai, GE Healthcare, Merck, Genentech. He serves on a data safety monitoring board for Johnson & Johnson. He is an Associate Editor for JAMA Neurology.F. Barkhof is a member of steering committee and safety monitoring boards for Merck, Biogen and Bayer. He is a consultant for Novartis, Roche, IXICO, GeNeuro, and Combinostics; his institutions received research support from EU\/EFPIA Innovative Medicines Initiative Joint Undertaking (EPAD and AMYPAD consortia), Horizon (EuroPOND), UK MS Society, IMDI-NOW (PICTURE), NIHR UCLH Biomedical Research Centre, and ECTRIMS-MAGNIMS. He is section Editor for Neuroradiology. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable (the work did not involve human nor animal participants)","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}